EDC for digital health clinical trials: ePRO, digital endpoints, and 21 CFR Part 11–aligned controls in one platform for DTx, SaMD, and digital biomarker studies.
21 CFR Part 11 aligned · HIPAA-aligned security · No credit card required
Digital therapeutics (DTx) and software as a medical device (SaMD) products require clinical evidence for regulatory clearance or approval. The FDA’s Digital Health Center of Excellence and equivalent international bodies expect clinical trial data generated with the same rigor as pharmaceutical or traditional medical device trials. This includes documented informed consent, validated data capture with audit trails, and clear data provenance from collection through analysis. For DTx companies, this creates a practical challenge: the intervention itself is digital, but the clinical trial infrastructure must meet traditional regulatory standards. Many DTx startups begin their clinical programs with consumer-grade data collection tools, only to discover that regulatory reviewers expect EDC-grade data governance when they submit for clearance. Capture provides the clinical trial infrastructure DTx and SaMD companies need from the start. The platform’s 21 CFR Part 11–aligned controls, electronic consent, and comprehensive audit trails are designed for regulatory submissions. And because Capture is priced for the startup and growth-stage companies that dominate the DTx landscape, teams can deploy clinical-grade data capture without the enterprise budgets that legacy EDC platforms require.
Digital health studies frequently combine multiple data sources: clinician assessments at study visits, patient self-reported outcomes via mobile devices, and measurements from digital health technologies (apps, wearables, sensors). Managing these data sources coherently is essential for data integrity and for presenting a unified dataset to regulators, reviewers, and analysis teams. Capture’s integrated approach addresses the two most common data sources directly: clinician-entered CRF data and patient-reported ePRO data share the same platform, audit trail, and access controls. For the third source—device- or sensor-generated data—study teams can define structured CRF fields that capture or document device endpoints within Capture, ensuring that the complete clinical dataset is accessible in one export. This approach acknowledges a practical reality: most digital health trials measure their primary and key secondary endpoints through clinical assessments and patient-reported outcomes. Device data often serves as an exploratory endpoint or supports the mechanism-of-action narrative. By providing clinical-grade capture for the endpoints that drive regulatory decisions and a structured framework for documenting digital endpoints, Capture ensures the most critical data has the strongest compliance foundation.
Regulatory agencies worldwide are developing and refining frameworks for digital health clinical evidence. The FDA’s guidance on digital health technologies as remote data acquisition tools in clinical investigations, the EU MDR requirements for software-based medical devices, and ICH E6(R3) modernization of GCP all emphasize that digital health data used in regulatory submissions must meet the same data integrity standards as traditional clinical trial data. For digital health companies, these expectations translate to specific requirements: electronic signatures for informed consent, comprehensive audit trails documenting every data point from creation through modification, role-based access controls preventing unauthorized data changes, and validated data export for statistical analysis and regulatory review. Capture’s compliance architecture addresses these requirements natively. The 21 CFR Part 11–aligned controls provide the electronic signatures, audit trails, and access controls that regulatory submissions require. HIPAA-aligned security protects participant data. And the Enterprise tier provides validation documentation that supports the sponsor’s regulatory submission strategy. For digital health companies planning regulatory submissions, using a compliant EDC from the earliest clinical studies avoids the costly scenario of re-running or supplementing studies because the original data capture system did not meet regulatory expectations.
Overview
Digital health clinical trials evaluate digital therapeutics (DTx), software as a medical device (SaMD), mobile health interventions, or digital biomarkers alongside traditional clinical endpoints. These trials generate data from multiple sources: clinician assessments during study visits, patient-reported outcomes collected via mobile devices, and digital endpoints derived from apps, wearables, or sensors. The EDC system must bring this heterogeneous data into a unified, auditable framework. The challenge for digital health trial teams is integration. Many digital health studies cobble together a clinical EDC for site-entered data, a separate ePRO vendor for patient-reported outcomes, a third platform for app- or sensor-generated data, and yet another system for informed consent. This fragmentation creates operational complexity: multiple logins for coordinators, separate audit trails that must be reconciled during monitoring, and integration costs that consume development resources better directed at the intervention itself. Capture addresses this by providing EDC, eConsent, and ePRO in one integrated platform with 21 CFR Part 11–aligned controls and HIPAA-aligned infrastructure. For digital health trials, this means clinician-entered CRF data and patient-reported outcomes share a single audit trail, consent is documented electronically within the same system, and the entire clinical dataset is accessible for monitoring and export without cross-system reconciliation. For wearable- or sensor-generated data that cannot be captured directly through Capture’s ePRO instruments, the platform supports structured documentation of device-collected endpoints alongside the clinical dataset. The study team defines the data model for device endpoints in Capture’s CRF builder, and data flows into the same export with all other study data. This approach ensures that the core clinical and patient-reported data—which constitute the primary and key secondary endpoints in most digital health trials—are captured in one compliant system.
Digital health trials face a unique convergence of clinical trial regulation and health technology complexity. Regulatory agencies including the FDA have issued guidance on digital health technologies (DHTs) used as endpoints in clinical investigations, emphasizing the importance of data integrity, participant consent documentation, and audit trails that cover the complete lifecycle of clinical data—regardless of whether the data originates from a clinic visit, a mobile app, or a wearable sensor. Traditional enterprise EDC platforms were designed for pharmaceutical trials with site-centered workflows. They handle CRF data well but treat ePRO and digital endpoints as bolt-on integrations requiring separate vendors, middleware, and reconciliation. For a startup developing a digital therapeutic, or a medical device company evaluating a companion app, these integration costs and timelines are disproportionate to the study scope. At the other end, lightweight data collection tools (survey platforms, consumer app analytics) may gather digital health data efficiently but lack the audit trails, electronic signatures, access controls, and data governance that regulatory submissions require. Capture occupies the right position for digital health trials: clinical-trial-grade compliance with modern, integrated modules for the data types digital health studies actually generate. ePRO is built into the platform—not bolted on—so patient-reported outcomes are captured with the same 21 CFR Part 11–aligned controls as clinician-entered data. eConsent documents participant agreement within the same system. And the browser-based CRF builder allows rapid iteration on study design, which matters in the fast-moving digital health development cycle.
FAQ
Explore the platform with a free sandbox. No sales call required.
Explore platform